STOCK TITAN
  1. Home
  2. News
  3. RCKT

Rocket Pharmaceuticals Inc - RCKT STOCK NEWS

Welcome to our dedicated news page for Rocket Pharmaceuticals (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rocket Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rocket Pharmaceuticals's position in the market.

News
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. announces that the European Medicines Agency accepted the Marketing Authorization Application for RP-L102, a gene therapy for Fanconi Anemia. Positive Phase 1/2 trial results show genetic and phenotypic correction extending to 42 months post-treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
none
-
News
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announces the appointment of Aaron Ondrey as Chief Financial Officer and key appointments within the corporate leadership team. Aaron Ondrey brings over 20 years of financial management experience. The company is preparing for a transition to the commercial stage and further pipeline development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
management
-
News
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. (RCKT) reports strong financial and operational results for Q4 and year-end 2023. The company is on track with its pipeline milestones for 2024 across various gene therapy programs. Rocket is expanding its commercial capabilities and expects a PDUFA date of June 30, 2024, for KRESLADI™. The company has a healthy cash position of approximately $407.5 million, providing operational runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
earnings
News
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. (RCKT) announces an extended PDUFA date of June 30, 2024 for KRESLADI™, a gene therapy for severe Leukocyte Adhesion Deficiency-I. Positive Phase 1/2 data shows 100% overall survival and significant improvements in patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
none
-
News
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) CEO to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
conferences
-
News
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) appoints R. Keith Woods as independent, non-executive director. With 30+ years' experience, Mr. Woods will support potential product launches for severe Leukocyte Adhesion Deficiency (LAD-I) and Fanconi Anemia (FA). He brings expertise from argenx and Alexion Pharmaceuticals, having generated over $1 billion in sales. Mr. Woods looks forward to helping Rocket realize its full potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
management
News
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
Rhea-AI Summary
Rocket Pharmaceuticals reports significant regulatory milestones and updates on pipeline developments. The company reached an agreement with the FDA on the Phase 2 pivotal study design of RP-L301 for PKD to support accelerated approval. They also initiated Phase 2 trials for RP-A501 for Danon Disease and Phase 1 trials for RP-A601 for PKP2-ACM. The FDA accepted the BLA for KRESLADITM (marnetegragene autotemcel) for severe LAD-I with a PDUFA target action date of March 31, 2024. Product filings for RP-L102 for Fanconi Anemia are anticipated in the first half of 2024. Rocket has cash, cash equivalents, and investments of approximately $437.2M, providing operational runway through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
earnings
-
News
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Rhea-AI Summary
Rocket Pharmaceuticals announces presentations at the 30th Annual Congress of the European Society of Gene & Cell Therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
-
News
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rhea-AI Summary
Rocket Pharmaceuticals receives FDA Priority Review for RP-L201 gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
clinical trial
News
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
Rhea-AI Summary
Rocket Pharmaceuticals CEO to participate in fireside chat at Chardan 7th Annual Genetic Medicines Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
conferences
Stock RCKT logo
Rocket Pharmaceuticals Inc

Nasdaq:RCKT

RCKT Rankings

#1866 Ranked by Market Cap
#2303 Ranked by Stock Gains
N/A Ranked by Dividends

RCKT Stock Data

2.19B
70.94M
3.66%
102.05%
11.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About RCKT

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.